share_log

马应龙(600993.SH):盐酸莫西沙星滴眼液获得药品注册证书

Mayinglong Pharmaceutical Group (600993.SH): The pharmaceutical registration certificate has been obtained for the moxifloxacin hydrochloride eye drops.

Gelonghui Finance ·  Aug 6 04:32

Mayinglong Pharmaceutical Group (600993.SH) announced that its wholly-owned subsidiary, Jiangxi Mayinglong Meikang Pharmaceutical Co., Ltd., has received the Drug Registration Certificate issued by the National Medical Products Administration for Moxifloxacin Hydrochloride Eye Drops. Moxifloxacin Hydrochloride Eye Drops is a fourth-generation fluoroquinolone antibacterial drug with broad-spectrum antibacterial activity.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment